SecBot SecBot
PTAB-TRIAL ·Filed Nov 10, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
NEUTRAL
Impact 3/10
Horizonmonths Processed6d 12h ago PTABPTAB Decision · ptacts.uspto.gov
PTAB institution decision (instituted)
Actionable Insight • Neutral

Monitor the trial schedule and any related district-court or ITC litigation that may be stayed or affected. The final written decision will determine whether claims are cancelled, which could impact Neurocrine's competitive position if the patent covers a product or therapy relevant to its pipeline.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$169.14
T+0 close · Nov 10, 2026 · via day close
Latest settled
+3.12%
T+1 · $174.41
Vs SPY
+1.80%
α at T+1
Next horizon
T+5
in 4h
  1. T+0 · Nov 10 $169.14entry
  2. T+1 · 6d ago +3.12%α +1.80% · $174.41
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

Executive Summary

The PTAB granted institution of post-grant review (PGR2026-00061) on Neurocrine's petition challenging claims of Spruce Biosciences' patent covering methods for treating testicular and ovarian adrenal rest tumors. This is an interlocutory ruling that opens a trial; no claims have been cancelled yet.

PTAB Trial Details

Proceeding
PGR2026-00061
Proceeding Type
PGR (post-grant review)
Decision
Trial instituted
Company Role
Petitioner
Outcome for Patent Owner
Pending (trial to come)
Patent
U.S. 12,576,084
Patent Covers
METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
Challenged Claims
not stated
Next Step
Final written decision due within approximately one year; scheduling order to follow

Key Facts

  • PTAB instituted PGR2026-00061 on November 10, 2026
  • Patent U.S. 12576084 covers methods for treating testicular and ovarian adrenal rest tumors
  • Neurocrine Biosciences is the petitioner; Spruce Biosciences is the patent owner
  • Institution granted means the Board found it more likely than not that at least one challenged claim is unpatentable
  • This is an interlocutory decision; a final written decision is expected within approximately one year

Financial Impact

Not quantifiable from the decision; the patent's materiality to Neurocrine's business is not stated

Risk Factors

  • Institution is interlocutory; no claims have been invalidated
  • The patent's connection to Neurocrine's products or revenue is not stated in the decision
  • Outcome uncertain until final written decision, which may be appealed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (37 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 PTAB decision.

DocumentAccession Number
PTAB-TRIAL Data (Synthetic)ptab-PGR2026-00061-ins-NBIX

Track record

30 reports on NBIX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Viewing Entry $169.14 Now $165.31 −2.26% settles Dec 9
  3. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  4. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  5. Nov 2, 202614d ago Press Release Bullish 6/10 No price data
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  8. Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
  9. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
  10. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
Showing 10 of 30

US Market Status

Market Closed · Opens in 6h 50m

Subscribe to SecBot

Get Real-Time PTAB Decision Intelligence

Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ PTAB Decision · ptacts.uspto.gov Report published Nov 10, 2026